<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font5" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font6" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font7" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font8" size="8" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font9" size="8" family="GillSans" color="#000000"/>
<text top="41" left="55" width="149" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Journal of Carcinogenesis 2005, 4 :19<i>Journal of Carcinogenesis</i></text>
<text top="41" left="371" width="183" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.carcinogenesis.com/content/4/1/19</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="106" segment_no="15" tag_type="text">Page 5 of 8<b>4</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="107" segment_no="16" tag_type="text">(page number not for citation purposes)</text>
<text top="251" left="55" width="36" height="10" font="font4" id="p1_t5" reading_order_no="32" segment_no="4" tag_type="title">Results</text>
<text top="263" left="55" width="241" height="9" font="font5" id="p1_t6" reading_order_no="33" segment_no="6" tag_type="text">Fifty-five cases of UM were studied. Eight seven percent of</text>
<text top="275" left="55" width="241" height="9" font="font5" id="p1_t7" reading_order_no="34" segment_no="6" tag_type="text">the tumors (n = 48) were classified as mixed cell type<i>(page number not for citation purposes)</i></text>
<text top="286" left="55" width="241" height="9" font="font5" id="p1_t8" reading_order_no="35" segment_no="6" tag_type="text">(spindle and epithelioid cells), 9% (n = 5) had predomi-<b>Results</b></text>
<text top="298" left="55" width="241" height="9" font="font5" id="p1_t9" reading_order_no="36" segment_no="6" tag_type="text">nance of epithelioid cells, and 3.6% (n = 2) of spindle</text>
<text top="310" left="55" width="21" height="9" font="font5" id="p1_t10" reading_order_no="37" segment_no="6" tag_type="text">cells.</text>
<text top="333" left="55" width="241" height="9" font="font5" id="p1_t11" reading_order_no="38" segment_no="8" tag_type="text">Seventy-eight percent of cases (n = 43) were found to be c-</text>
<text top="345" left="55" width="241" height="9" font="font5" id="p1_t12" reading_order_no="39" segment_no="8" tag_type="text">kit positive (Figure 1A). Among the positive cases, 46.5%</text>
<text top="357" left="55" width="241" height="9" font="font5" id="p1_t13" reading_order_no="40" segment_no="8" tag_type="text">(n = 20) presented with what was considered as high</text>
<text top="369" left="55" width="241" height="9" font="font5" id="p1_t14" reading_order_no="41" segment_no="8" tag_type="text">expression. All lesions with high immunoreactivity (n =</text>
<text top="380" left="55" width="241" height="9" font="font5" id="p1_t15" reading_order_no="42" segment_no="8" tag_type="text">20) had cytoplasmic and cell membrane expression.<a href="">1A). Amon</a>g the positive cases, 46.5%</text>
<text top="392" left="55" width="241" height="9" font="font5" id="p1_t16" reading_order_no="43" segment_no="8" tag_type="text">Meanwhile, among lesions with low immunoreactivity (n</text>
<text top="404" left="55" width="241" height="9" font="font5" id="p1_t17" reading_order_no="44" segment_no="8" tag_type="text">= 23), 100% presented a cytoplasmatic reaction and just</text>
<text top="416" left="55" width="241" height="9" font="font5" id="p1_t18" reading_order_no="45" segment_no="8" tag_type="text">30.4% (n = 7) presented with a cell membrane stain-pat-</text>
<text top="427" left="55" width="111" height="9" font="font5" id="p1_t19" reading_order_no="46" segment_no="8" tag_type="text">tern (Figure 1B). (Table 1)</text>
<text top="451" left="55" width="241" height="9" font="font5" id="p1_t20" reading_order_no="47" segment_no="10" tag_type="text">The percent invasion of cell lines according to the baseline</text>
<text top="463" left="55" width="241" height="9" font="font5" id="p1_t21" reading_order_no="48" segment_no="10" tag_type="text">invasion without imatinib mesylate was: MKT-BR</text>
<text top="474" left="55" width="241" height="9" font="font5" id="p1_t22" reading_order_no="49" segment_no="10" tag_type="text">(38.4%) &gt; OCM-1 (21.7%) &gt; 92.1 (14.4%) &gt; UW-1<a href="">1B). (Table 1)</a></text>
<text top="486" left="55" width="241" height="9" font="font5" id="p1_t23" reading_order_no="50" segment_no="10" tag_type="text">(12%) &gt; SP6.5 (3%). The addition of imatinib mesylate</text>
<text top="498" left="55" width="241" height="9" font="font5" id="p1_t24" reading_order_no="51" segment_no="10" tag_type="text">decreased the invasion in all cell lines: MKT-BR (1.03%);</text>
<text top="510" left="55" width="241" height="9" font="font5" id="p1_t25" reading_order_no="52" segment_no="10" tag_type="text">OCM-1 (0.1%); 92.1 (0.2%); UW-1 (0%); SP6.5 (0%).</text>
<text top="521" left="55" width="141" height="9" font="font5" id="p1_t26" reading_order_no="53" segment_no="10" tag_type="text">The results are shown in Figure 3.</text>
<text top="545" left="55" width="241" height="9" font="font5" id="p1_t27" reading_order_no="54" segment_no="11" tag_type="text">No visible changes in cytomorphology were seen in reac-</text>
<text top="557" left="55" width="218" height="9" font="font5" id="p1_t28" reading_order_no="55" segment_no="11" tag_type="text">tion to the presence of imatinib mesylate (figure 2).</text>
<text top="580" left="55" width="241" height="9" font="font5" id="p1_t29" reading_order_no="56" segment_no="12" tag_type="text">Statistically significant differences between the invasion<a href="">re 3.</a></text>
<text top="592" left="55" width="241" height="9" font="font5" id="p1_t30" reading_order_no="57" segment_no="12" tag_type="text">rates for the control group and imatinib mesylate group</text>
<text top="604" left="55" width="209" height="9" font="font5" id="p1_t31" reading_order_no="58" segment_no="12" tag_type="text">were found in all cell lines (T test p value &lt; 0.05).<a href="">te (figure 2).</a></text>
<text top="627" left="55" width="241" height="9" font="font5" id="p1_t32" reading_order_no="59" segment_no="14" tag_type="text">Figure 4 depicts the results from the Sulforhodamine-B</text>
<text top="639" left="55" width="241" height="9" font="font5" id="p1_t33" reading_order_no="60" segment_no="14" tag_type="text">assay. The mean and standard deviation for each cell line</text>
<text top="651" left="55" width="241" height="9" font="font5" id="p1_t34" reading_order_no="61" segment_no="14" tag_type="text">per condition is shown in Table 2. Cells that were directly</text>
<text top="662" left="55" width="241" height="9" font="font5" id="p1_t35" reading_order_no="62" segment_no="14" tag_type="text">exposed imatinib mesylate showed a decrease in prolifer-<a href="">gure 4 </a>depicts the results from the Sulforhodamine-B</text>
<text top="674" left="55" width="241" height="9" font="font5" id="p1_t36" reading_order_no="63" segment_no="14" tag_type="text">ation for all five human cell lines (92.1, MKT-BR, OCM-1,</text>
<text top="686" left="55" width="241" height="9" font="font5" id="p1_t37" reading_order_no="64" segment_no="14" tag_type="text">SP6.5, UW-1) as compared to control (p value of<a href="">in Table 2. Cells that were directly</a></text>
<text top="697" left="55" width="242" height="10" font="font5" id="p1_t38" reading_order_no="65" segment_no="14" tag_type="text">0.001354991, 0.012655861, 9.47698 × 10 -7 ,</text>
<text top="709" left="55" width="197" height="9" font="font5" id="p1_t39" reading_order_no="66" segment_no="14" tag_type="text">0.002754018 and 5.79576 × 10 -6 respectively).</text>
<text top="251" left="313" width="52" height="10" font="font4" id="p1_t40" reading_order_no="67" segment_no="5" tag_type="title">Discussion</text>
<text top="263" left="313" width="241" height="9" font="font5" id="p1_t41" reading_order_no="68" segment_no="7" tag_type="text">It is known that protein tyrosine kinases (PTK) have an</text>
<text top="275" left="313" width="241" height="9" font="font5" id="p1_t42" reading_order_no="69" segment_no="7" tag_type="text">important role in cellular mechanisms, such as differenti-</text>
<text top="286" left="313" width="241" height="9" font="font5" id="p1_t43" reading_order_no="70" segment_no="7" tag_type="text">ation, proliferation and regulatory mechanisms, as well as</text>
<text top="298" left="313" width="241" height="9" font="font5" id="p1_t44" reading_order_no="71" segment_no="7" tag_type="text">in signal transduction. C-kit is one of these PTK, which is</text>
<text top="310" left="313" width="241" height="9" font="font5" id="p1_t45" reading_order_no="72" segment_no="7" tag_type="text">expressed in a wide variety of human malignancies [16]</text>
<text top="322" left="313" width="241" height="9" font="font5" id="p1_t46" reading_order_no="73" segment_no="7" tag_type="text">including chronic and acute myelogenous leukemia [6],</text>
<text top="333" left="313" width="241" height="9" font="font5" id="p1_t47" reading_order_no="74" segment_no="7" tag_type="text">GIST [7], mastocytosis [17], small cell lung carcinoma<b>Discussion</b></text>
<text top="345" left="313" width="241" height="9" font="font5" id="p1_t48" reading_order_no="75" segment_no="7" tag_type="text">[18], chromophobe renal cell carcinoma [19], cutaneous</text>
<text top="357" left="313" width="241" height="9" font="font5" id="p1_t49" reading_order_no="76" segment_no="7" tag_type="text">[20] and UM [16]. As c-kit is expressed in normal</text>
<text top="369" left="313" width="241" height="9" font="font5" id="p1_t50" reading_order_no="77" segment_no="7" tag_type="text">interstitial cells of Cajal, the progenitor cell of GIST [7],</text>
<text top="380" left="313" width="241" height="9" font="font5" id="p1_t51" reading_order_no="78" segment_no="7" tag_type="text">the present article studies the expression of c-kit in uveal</text>
<text top="392" left="313" width="241" height="9" font="font5" id="p1_t52" reading_order_no="79" segment_no="7" tag_type="text">melanomas, as normal choroidal melanocytes do express<a href="">[16]</a></text>
<text top="404" left="313" width="71" height="9" font="font5" id="p1_t53" reading_order_no="80" segment_no="7" tag_type="text">this marker [21].<a href="">6</a>],</text>
<text top="427" left="313" width="241" height="9" font="font5" id="p1_t54" reading_order_no="81" segment_no="9" tag_type="text">We demonstrated that more than 75% of UM from our<a href="">7], mastocy</a>t<a href="">osis [17]</a>, small cell lung carcinoma</text>
<text top="439" left="313" width="241" height="9" font="font5" id="p1_t55" reading_order_no="82" segment_no="9" tag_type="text">series are positive for c-kit. This finding, per se, supports<a href="">[18</a>], chromophobe renal cell carc<a href="">inoma [19], cutaneou</a>s</text>
<text top="451" left="313" width="241" height="9" font="font5" id="p1_t56" reading_order_no="83" segment_no="9" tag_type="text">the idea of a clinical trial of imatinib mesylate for UM,<a href="">[20</a>] and UM<a href=""> [16]. As </a>c-kit is expressed in normal</text>
<text top="463" left="313" width="241" height="9" font="font5" id="p1_t57" reading_order_no="84" segment_no="9" tag_type="text">especially in metastatic cases. Once metastatic disease is<a href="">7</a>],</text>
<text top="474" left="313" width="241" height="9" font="font5" id="p1_t58" reading_order_no="85" segment_no="9" tag_type="text">detected, no effective method of systemic therapy has</text>
<text top="486" left="313" width="241" height="9" font="font5" id="p1_t59" reading_order_no="86" segment_no="9" tag_type="text">been identified [3]. Moreover, not 100% of GIST is posi-</text>
<text top="498" left="313" width="241" height="9" font="font5" id="p1_t60" reading_order_no="87" segment_no="9" tag_type="text">tive for c-kit. In fact, 6% of GIST are c-kit negative [22].<a href="">21]</a>.</text>
<text top="510" left="313" width="241" height="9" font="font5" id="p1_t61" reading_order_no="88" segment_no="9" tag_type="text">Before the imatinib mesylate "era", metastatic GIST had a</text>
<text top="521" left="313" width="241" height="9" font="font5" id="p1_t62" reading_order_no="89" segment_no="9" tag_type="text">median survival times ranging between 10–20 months</text>
<text top="533" left="313" width="241" height="9" font="font5" id="p1_t63" reading_order_no="90" segment_no="9" tag_type="text">[23]. Nowadays, imatinib mesylate controls tumor</text>
<text top="545" left="313" width="241" height="9" font="font5" id="p1_t64" reading_order_no="91" segment_no="9" tag_type="text">growth in up to 85% of advanced GIST [24], with 90% of</text>
<text top="557" left="313" width="100" height="9" font="font5" id="p1_t65" reading_order_no="92" segment_no="9" tag_type="text">acceptable toxicity [25].</text>
<text top="580" left="313" width="241" height="9" font="font5" id="p1_t66" reading_order_no="93" segment_no="13" tag_type="text">In cutaneous melanoma, c-kit is strongly expressed in<a href=""> [3]. </a>Moreover, not 100% of GIST is posi-</text>
<text top="592" left="313" width="241" height="9" font="font5" id="p1_t67" reading_order_no="94" segment_no="13" tag_type="text">radial growth phase, and weak or no expression is seen in<a href="">kit negative [22</a>].</text>
<text top="604" left="313" width="241" height="9" font="font5" id="p1_t68" reading_order_no="95" segment_no="13" tag_type="text">vertical growth phase and metastatic disease [26].</text>
<text top="615" left="313" width="241" height="9" font="font5" id="p1_t69" reading_order_no="96" segment_no="13" tag_type="text">Therefore, in cutaneous melanomas c-kit expression</text>
<text top="627" left="313" width="241" height="9" font="font5" id="p1_t70" reading_order_no="97" segment_no="13" tag_type="text">appears to be related with stage of the disease. To further<a href="">[23</a>]. Nowadays, imatinib mesylate controls tumor</text>
<text top="639" left="313" width="241" height="9" font="font5" id="p1_t71" reading_order_no="98" segment_no="13" tag_type="text">investigate a similar expression of the c-kit in UM, we<a href="">24]</a>, with 90% of</text>
<text top="651" left="313" width="241" height="9" font="font5" id="p1_t72" reading_order_no="99" segment_no="13" tag_type="text">observed the cell type (spindle and epithelioid) in which<a href=""> [25].</a></text>
<text top="662" left="313" width="241" height="9" font="font5" id="p1_t73" reading_order_no="100" segment_no="13" tag_type="text">the c-kit was expressed, as it is well known that spindle cell</text>
<text top="674" left="313" width="241" height="9" font="font5" id="p1_t74" reading_order_no="101" segment_no="13" tag_type="text">type is less aggressive than epithelioid type [1]. None of</text>
<text top="686" left="313" width="241" height="9" font="font5" id="p1_t75" reading_order_no="102" segment_no="13" tag_type="text">the previous studies recorded the cell type in which the<a href=""> [26</a>].</text>
<text top="698" left="313" width="241" height="9" font="font5" id="p1_t76" reading_order_no="103" segment_no="13" tag_type="text">expression was occurring. Mouriaux et al [21] compared</text>
<text top="709" left="313" width="241" height="9" font="font5" id="p1_t77" reading_order_no="104" segment_no="13" tag_type="text">the c-kit expression with cell type tumor (Callendar's clas-</text>
<text top="721" left="313" width="241" height="9" font="font5" id="p1_t78" reading_order_no="105" segment_no="13" tag_type="text">sification) as a correlation to prognostic factor, but did</text>
<text top="87" left="55" width="486" height="7" font="font8" id="p1_t79" reading_order_no="2" segment_no="2" tag_type="title">Table 2: Number of cells counted per control membrane, and percent invasion (mean ± standard deviation) of cells in response to</text>
<text top="96" left="55" width="93" height="7" font="font8" id="p1_t80" reading_order_no="3" segment_no="2" tag_type="title">experimental conditions.</text>
<text top="114" left="100" width="34" height="7" font="font8" id="p1_t81" reading_order_no="4" segment_no="3" tag_type="table">Cell Line<a href="">1</a>]. None of</text>
<text top="114" left="189" width="110" height="7" font="font8" id="p1_t82" reading_order_no="5" segment_no="3" tag_type="table">Average Number of Cells in</text>
<text top="124" left="218" width="49" height="7" font="font8" id="p1_t83" reading_order_no="6" segment_no="3" tag_type="table">Control PET</text>
<text top="114" left="315" width="107" height="7" font="font8" id="p1_t84" reading_order_no="7" segment_no="3" tag_type="table">Percent Invasion of Cells in<i>et al </i></text>
<text top="124" left="326" width="82" height="7" font="font8" id="p1_t85" reading_order_no="8" segment_no="3" tag_type="table">Response to 10% FBS<a href="">[21</a>] compared</text>
<text top="114" left="439" width="107" height="7" font="font8" id="p1_t86" reading_order_no="9" segment_no="3" tag_type="table">Percent Invasion of Cells in</text>
<text top="124" left="451" width="84" height="7" font="font8" id="p1_t87" reading_order_no="10" segment_no="3" tag_type="table">Response to Imatinib</text>
<text top="133" left="474" width="35" height="7" font="font8" id="p1_t88" reading_order_no="11" segment_no="3" tag_type="table">mesylate<b>Table 2: Number of cells counted per control membrane, and percent invasion (mean ± standard deviation) of cells in response to </b></text>
<text top="155" left="103" width="29" height="7" font="font9" id="p1_t89" reading_order_no="12" segment_no="3" tag_type="table">MKT-BR<b>experimental conditions.</b></text>
<text top="155" left="236" width="12" height="7" font="font9" id="p1_t90" reading_order_no="13" segment_no="3" tag_type="table">247<b>Cell Line</b></text>
<text top="155" left="345" width="43" height="7" font="font9" id="p1_t91" reading_order_no="14" segment_no="3" tag_type="table">38.43% ± 8.5<b>Average Number of Cells in </b></text>
<text top="155" left="472" width="39" height="7" font="font9" id="p1_t92" reading_order_no="15" segment_no="3" tag_type="table">1.03% ± 0.2<b>Control PET</b></text>
<text top="165" left="105" width="26" height="7" font="font9" id="p1_t93" reading_order_no="16" segment_no="3" tag_type="table">OCM-1<b>Percent Invasion of Cells in </b></text>
<text top="165" left="231" width="22" height="7" font="font9" id="p1_t94" reading_order_no="17" segment_no="3" tag_type="table">246.67<b>Response to 10% FBS</b></text>
<text top="165" left="347" width="39" height="7" font="font9" id="p1_t95" reading_order_no="18" segment_no="3" tag_type="table">21.7% ± 1.9<b>Percent Invasion of Cells in </b></text>
<text top="165" left="474" width="35" height="7" font="font9" id="p1_t96" reading_order_no="19" segment_no="3" tag_type="table">0.1% ± 0.2<b>Response to Imatinib </b></text>
<text top="176" left="110" width="14" height="7" font="font9" id="p1_t97" reading_order_no="20" segment_no="3" tag_type="table">92.1<b>mesylate</b></text>
<text top="176" left="236" width="12" height="7" font="font9" id="p1_t98" reading_order_no="21" segment_no="3" tag_type="table">223</text>
<text top="176" left="347" width="39" height="7" font="font9" id="p1_t99" reading_order_no="22" segment_no="3" tag_type="table">14.4% ± 2.7</text>
<text top="176" left="474" width="35" height="7" font="font9" id="p1_t100" reading_order_no="23" segment_no="3" tag_type="table">0.2% ± 0.2</text>
<text top="186" left="107" width="21" height="7" font="font9" id="p1_t101" reading_order_no="24" segment_no="3" tag_type="table">UW-1</text>
<text top="186" left="233" width="18" height="7" font="font9" id="p1_t102" reading_order_no="25" segment_no="3" tag_type="table">66.33</text>
<text top="186" left="350" width="33" height="7" font="font9" id="p1_t103" reading_order_no="26" segment_no="3" tag_type="table">12% ± 4.8</text>
<text top="186" left="480" width="23" height="7" font="font9" id="p1_t104" reading_order_no="27" segment_no="3" tag_type="table">0% ± 0</text>
<text top="196" left="108" width="18" height="7" font="font9" id="p1_t105" reading_order_no="28" segment_no="3" tag_type="table">SP6.5</text>
<text top="196" left="236" width="12" height="7" font="font9" id="p1_t106" reading_order_no="29" segment_no="3" tag_type="table">266</text>
<text top="196" left="352" width="29" height="7" font="font9" id="p1_t107" reading_order_no="30" segment_no="3" tag_type="table">3% ± 1.5</text>
<text top="196" left="480" width="23" height="7" font="font9" id="p1_t108" reading_order_no="31" segment_no="3" tag_type="table">0% ± 0</text>
</page>
</pdf2xml>
